Generic Supply Chain

Dear Mr. President—On the Eve of Your Drug-Pricing Speech

A virtuous cycle of innovation and access has served as the foundation for our nation’s prescription drug market since the presidency of Ronald Reagan. When that market worked as Congress originally intended around the time of enactment of the Hatch-Waxman amendments in the 1980s, patients benefited from lifesaving new drugs; they maintained their health with generic medicines; brand drug makers recouped their investments, rewarded shareholders and were incentivized to discover new therapies and cures; and the makers of generics had thriving businesses.

2017 AAM Annual Report

2017 Was Epic

The landscape around us looks much different today than it did just one year ago. As our industry changes within the evolving pharmaceutical ecosystem, we must speak with one voice to drive home the message that a robust generic drug and biosimilars marketplace is necessary to sustain affordable health care.

AAM White Paper: Ensuring the Future of Accessible Medicines in the U.S.

Patient health and well-being depends on the uninterrupted availability of lower-cost generic and biosimilar medicines. Moreover, as patients live longer the importance of a robust and sustainable generic and biosimilar medicines industry becomes only that much more important. Policymakers must act quickly to ensure continued saving and market-based competition, as well as prevent shortages, for future availability of affordable medicines. This requires:

7 Policy Solutions

Association for Accessible Medicines is calling on Congress to take meaningful action to lower prescription drug costs with the Prescription for Savings. Patients win when market-based competition from FDA-approved generics and biosimilars deliver savings at the pharmacy counter.

To this end, we recommend these seven policy solutions:

#EndtheShenanigans, Says Gottlieb

Dr. Scott Gottlieb, Commissioner of Food and Drugs, has adopted a bold stance on behalf of patient access to affordable medicines. In particular, he is targeting REMS abuse — by which some bad actors prevent generic firms from purchasing the doses of a branded drug that they need to run their studies — for the way it undermines the sustainable competition necessary for FDA-approved generic drugs and biosimilars to reach patients.

Subscribe to Generic Supply Chain

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.